Hyperbaric oxygen promotes not only glioblastoma proliferation but also chemosensitization by inhibiting HIF1α/HIF2α-Sox2.

Hyperbaric oxygen promotes not only glioblastoma proliferation but also chemosensitization by inhibiting HIF1α/HIF2α-Sox2.
复制标题

高压氧不仅促进胶质母细胞瘤增殖,还通过抑制 HIF1α/HIF2α-Sox2 促进化疗增敏

DOI:
10.1038/s41420-021-00486-0
复制
发表时间:
2021-05-13
影响因子:
7
通讯作者:
Liao B
Liao B
中科院分区:
医学2区
文献类型:
--
作者:
Wang P;Gong S;Pan J;Wang J;Zou D;Xiong S;Zhao L;Yan Q;Deng Y;Wu N;Liao B

文献摘要

参考文献

被引文献

相似文献

高压氧(HBO)联合化疗可提高GBM细胞对化疗的敏感性。然而,很少有研究探讨了其中的机制。HIF 1 α和HIF 2 α是通过抑制细胞凋亡或在缺氧条件下维持干性而促进GBM恶性进展的两种主要分子。此外,Sox 2,一种干性标志物,也有助于通过干性维持或细胞周期停滞GBM恶性进展。简而言之,HIF 1 α、HIF 2 α和Sox 2在缺氧条件下高度表达,并有助于GBM生长和化学抗性。然而,高压氧暴露于GBM后,上述因子的表达是否降低,从而导致化疗增敏,目前尚不清楚。因此,我们进行了一系列研究,并确定了HBO后HIF 1 α、HIF 2 α和Sox 2的表达降低,HBO通过细胞周期进程促进GBM细胞增殖,尽管干细胞减少,从而通过抑制HIF 1 α/HIF 2 α-Sox 2促进化学增敏。
There exists a consensus that combining hyperbaric oxygen (HBO) and chemotherapy promotes chemotherapy sensitivity in GBM cells. However, few studies have explored the mechanism involved. HIF1α and HIF2α are the two main molecules that contribute to GBM malignant progression by inhibiting apoptosis or maintaining stemness under hypoxic conditions. Moreover, Sox2, a marker of stemness, also contributes to GBM malignant progression through stemness maintenance or cell cycle arrest. Briefly, HIF1α, HIF2α and Sox2 are highly expressed under hypoxia and contribute to GBM growth and chemoresistance. However, after exposure to HBO for GBM, whether the expression of the above factors is decreased, resulting in chemosensitization, remains unknown. Therefore, we performed a series of studies and determined that the expression of HIF1α, HIF2α and Sox2 was decreased after HBO and that HBO promoted GBM cell proliferation through cell cycle progression, albeit with a decrease in stemness, thus contributing to chemosensitization via the inhibition of HIF1α/HIF2α-Sox2.
神经胶质瘤、肝癌和肺癌在缺氧条件下可以通过去分化诱导癌症干细胞样细胞
DOI: 10.1038/cddiscovery.2016.105
发表时间: 2017
影响因子: 7
作者:
Wang P;Wan WW;Xiong SL;Feng H;Wu N
通讯作者: Wu N
DOI: 10.1007/s12032-016-0814-0
发表时间: 2016-09
期刊: Medical oncology (Northwood, London, England)
影响因子: --
作者:
Stępień K;Ostrowski RP;Matyja E
通讯作者: Matyja E
DOI: 10.1007/s13402-018-0374-8
发表时间: 2018-06
期刊: Cellular oncology (Dordrecht, Netherlands)
影响因子: --
作者:
Ahmed EM;Bandopadhyay G;Coyle B;Grabowska A
通讯作者: Grabowska A
DOI: 10.3892/ol.2015.3244
发表时间: 2015-07-01
期刊: ONCOLOGY LETTERS
影响因子: 2.9
作者:
Wang, Yong-Gang;Zhan, Yi-Ping;Yu, Chun-Jiang
通讯作者: Yu, Chun-Jiang
DOI: 10.1038/nm.2865
发表时间: 2012-07-06
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Young, Regina M.;Simon, M. Celeste
通讯作者: Simon, M. Celeste